http://www.americanbankingnews.com/getthestreet reiterated their buy rating on shares of Allergan (NYSE: AGN) in a research note issued to investors on Wednesday.
“Allergan (AGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of A+ . The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”
,” TheStreet’s analyst wrote.
TheStreet has also updated their ratings on a number of other healthcare stocks in the last week. The firm reiterated its buy rating on shares of Alexion Pharmaceuticals. Also, TheStreet reiterated its sell rating on shares of Vertex Pharmaceuticals.
Allergan opened at 108.42 on Wednesday. Allergan has a 1-year low of $81.28 and a 1-year high of $109.31. The stock’s 50-day moving average is currently $106.3. The company has a market cap of $32.504 billion and a price-to-earnings ratio of 30.28.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, March 21st. Shareholders of record on Thursday, February 28th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.18%. The ex-dividend date of this dividend is Tuesday, February 26th.
A number of other firms have also recently commented on AGN. Analysts at SunTrust reiterated a buy rating on shares of Allergan in a research note to investors on Thursday, February 21st. They now have a $121.00 price target on the stock. Separately, analysts at Zacks reiterated a neutral rating on shares of Allergan in a research note to investors on Thursday, February 7th. They now have a $114.00 price target on the stock. Finally, analysts at Citigroup raised their price target on shares of Allergan from $106.00 to $124.00 in a research note to investors on Thursday, February 7th. They now have a buy rating on the stock.
Twenty investment analysts have rated the stock with a buy rating, two have assigned an overweight rating, and seven have assigned a hold rating to the company. The company presently has an average rating of overweight and a consensus target price of $114.73.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
